{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:53:02Z","timestamp":1791942782017,"version":"4.3.4"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chronic headache due to the overuse of medication for the treatment of migraine attacks has a prevalence of 0.5\u20132.0%. This guideline provides guidance for the management of medication overuse (MO) and medication overuse headache (MOH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recommendations<\/jats:title>\n                    <jats:p>Treatment of headache due to overuse of analgesics or specific migraine medications involves several stages. Patients with medication overuse (MO) or medication overuse headache (MOH) should be educated about the relationship between frequent use of symptomatic headache medication and the transition from episodic to chronic migraine (chronification), with the aim of reducing and limiting the use of acute medication. In a second step, migraine prophylaxis should be initiated in patients with migraine and overuse of analgesics or specific migraine drugs. Topiramate, onabotulinumtoxinA and the monoclonal antibodies against CGRP or the CGRP-receptor are effective in patients with chronic migraine and medication overuse. In patients with tension-type headache, prophylaxis is performed with amitriptyline. Drug prophylaxis should be supplemented by non-drug interventions. For patients in whom education and prophylactic medication are not effective, pausing acute medication is recommended. This treatment can be performed in an outpatient, day hospital or inpatient setting. Patients with headache due to overuse of opioids should undergo inpatient withdrawal. The success rate of the stepped treatment approach is 50\u201370% after 6 to 12\u00a0months. A high relapse rate is observed in patients with opioid overuse. Tricyclic antidepressants, neuroleptics (antiemetics) and the administration of steroids are recommended for the treatment of withdrawal symptoms or headaches during the medication pause. Consistent patient education and further close monitoring reduce the risk of relapse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42466-022-00200-0","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T22:02:31Z","timestamp":1661724151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline"],"prefix":"10.1186","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-8612","authenticated-orcid":false,"given":"Hans-Christoph","family":"Diener","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kropp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dresler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"F\u00f6rderreuther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagny","family":"Holle-Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Niederberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"issue":"2","key":"200_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1468-2982.2009.01906.x","volume":"30","author":"A Straube","year":"2010","unstructured":"Straube, A., Pfaffenrath, V., Ladwig, K. H., Meisinger, C., Hoffmann, W., Fendrich, K., et al. (2010). Prevalence of chronic migraine and medication overuse headache in Germany\u2014The German DMKG headache study. Cephalalgia, 30(2), 207\u2013213.","journal-title":"Cephalalgia"},{"issue":"5","key":"200_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde, M., Gustavsson, A., Stovner, L. J., Steiner, T. J., Barre, J., Katsarava, Z., et al. (2012). The cost of headache disorders in Europe: The Eurolight project. European Journal of Neurology, 19(5), 703\u2013711.","journal-title":"European Journal of Neurology"},{"issue":"1","key":"200_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (HIS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (HIS). (2018). The International Classification of Headache Disorders ICHD-3, 3rd edition. Cephalalgia, 38(1), 1\u2013211.","journal-title":"Cephalalgia"},{"key":"200_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1055\/s-2008-1069197","volume":"109","author":"J Dichgans","year":"1984","unstructured":"Dichgans, J., Diener, H. C., Gerber, W. D., Verspohl, E. J., Kukiolka, H., & Kluck, M. (1984). Analgetika-induzierter Dauerkopfschmerz. Dtsch med Wschr., 109, 369\u2013373.","journal-title":"Dtsch med Wschr."},{"key":"200_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1526-4610.1963.hed0204214.x","volume":"3","author":"BT Horton","year":"1963","unstructured":"Horton, B. T., & Peters, G. A. (1963). Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: Report of 52 cases. Headache, 3, 214\u2013226.","journal-title":"Headache"},{"key":"200_CR6","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1136\/bmj.308.6943.1573d","volume":"308","author":"H Kaube","year":"1994","unstructured":"Kaube, H., May, A., Diener, H. C., & Pfaffenrath, V. (1994). Sumatriptan misuse in daily chronic headache. BMJ, 308, 1573.","journal-title":"BMJ"},{"issue":"8","key":"200_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(04)00824-5","volume":"3","author":"HC Diener","year":"2004","unstructured":"Diener, H. C., & Limmroth, V. (2004). Medication-overuse headache: A worldwide problem. Lancet Neurology, 3(8), 475\u2013483.","journal-title":"Lancet Neurology"},{"issue":"2","key":"200_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098614522683","volume":"5","author":"ES Kristoffersen","year":"2014","unstructured":"Kristoffersen, E. S., & Lundqvist, C. (2014). Medication-overuse headache: Epidemiology, diagnosis and treatment. Therapeutic Advances in Drug Safety, 5(2), 87\u201399.","journal-title":"Therapeutic Advances in Drug Safety"},{"issue":"11","key":"200_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"Global Burden of Disease Neurological Disorders Collaborator Group","year":"2017","unstructured":"Global Burden of Disease Neurological Disorders Collaborator Group. (2017). Global, regional, and national burden of neurological disorders during 1990\u20132015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurology, 16(11), 877\u2013897.","journal-title":"Lancet Neurology"},{"issue":"2","key":"200_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1212\/01.wnl.0000183555.54305.fd","volume":"66","author":"SJ Wang","year":"2006","unstructured":"Wang, S. J., Fuh, J. L., Lu, S. R., & Juang, K. D. (2006). Chronic daily headache in adolescents: Prevalence, impact, and medication overuse. Neurology, 66(2), 193\u2013197.","journal-title":"Neurology"},{"issue":"6","key":"200_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/0333102413512033","volume":"34","author":"ML Westergaard","year":"2014","unstructured":"Westergaard, M. L., Hansen, E. H., Glumer, C., Olesen, J., & Jensen, R. H. (2014). Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: A systematic review. Cephalalgia, 34(6), 409\u2013425.","journal-title":"Cephalalgia"},{"issue":"S6","key":"200_CR12","first-page":"2","volume":"5","author":"M Porst","year":"2020","unstructured":"Porst, M., Wengler, A., Leddin, J., Neuhauser, H., Katsarava, Z., von der Lippe, E., et al. (2020). Migraine and tension-type headache in Germany. Prevalence and disease severity from the BURDEN 2020 Burden of Disease Study. Journal of Health Monitoring., 5(S6), 2\u201324.","journal-title":"Journal of Health Monitoring."},{"key":"200_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1129-2377-14-40","volume":"14","author":"SH Schramm","year":"2013","unstructured":"Schramm, S. H., Obermann, M., Katsarava, Z., Diener, H. C., Moebus, S., & Yoon, M. S. (2013). Epidemiological profiles of patients with chronic migraine and chronic tension-type headache. The Journal of Headache and Pain, 14, 40.","journal-title":"The Journal of Headache and Pain"},{"issue":"5","key":"200_CR14","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1212\/01.WNL.0000113747.18760.D2","volume":"62","author":"Z Katsarava","year":"2004","unstructured":"Katsarava, Z., Schneeweiss, S., Kurth, T., Kroener, U., Fritsche, G., Eikermann, A., et al. (2004). Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology, 62(5), 788\u2013790.","journal-title":"Neurology"},{"issue":"7","key":"200_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1212\/WNL.59.7.1011","volume":"59","author":"V Limmroth","year":"2002","unstructured":"Limmroth, V., Katsarava, Z., Fritsche, G., Przywara, S., & Diener, H. C. (2002). Features of medication overuse headache following overuse of different acute headache drugs. Neurology, 59(7), 1011\u20131014.","journal-title":"Neurology"},{"issue":"4","key":"200_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1526-4610.2009.01365.x","volume":"49","author":"C Cr\u00e9ac'h","year":"2009","unstructured":"Cr\u00e9ac\u2019h, C., Radat, F., Mick, G., Guegan-Massardier, E., Giraud, P., Guy, N., et al. (2009). One or several types of triptan overuse headaches? Headache: The Journal of Head and Face Pain, 49(4), 519\u2013528.","journal-title":"Headache: The Journal of Head and Face Pain"},{"issue":"8","key":"200_CR17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1468-2982.2008.01819.x","volume":"29","author":"ME Bigal","year":"2009","unstructured":"Bigal, M. E., Borucho, S., Serrano, D., & Lipton, R. B. (2009). The acute treatment of episodic and chronic migraine in the USA. Cephalalgia, 29(8), 891\u2013897.","journal-title":"Cephalalgia"},{"issue":"1","key":"200_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s10194-016-0696-8","volume":"17","author":"K Thorlund","year":"2016","unstructured":"Thorlund, K., Sun-Edelstein, C., Druyts, E., Kanters, S., Ebrahim, S., Bhambri, R., et al. (2016). Risk of medication overuse headache across classes of treatments for acute migraine. The Journal of Headache and Pain, 17(1), 107.","journal-title":"The Journal of Headache and Pain"},{"issue":"1","key":"200_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s10194-017-0806-2","volume":"18","author":"RB Lipton","year":"2017","unstructured":"Lipton, R. B., Diener, H. C., Robbins, M. S., Garas, S. Y., & Patel, K. (2017). Caffeine in the management of patients with headache. The Journal of Headache and Pain, 18(1), 107.","journal-title":"The Journal of Headache and Pain"},{"issue":"2","key":"200_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1468-2982.2008.01710.x","volume":"29","author":"P Zeeberg","year":"2009","unstructured":"Zeeberg, P., Olesen, J., & Jensen, R. (2009). Medication overuse headache and chronic migraine in a specialized headache centre: Field-testing proposed new appendix criteria. Cephalalgia, 29(2), 214\u2013220.","journal-title":"Cephalalgia"},{"issue":"1","key":"200_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1526-4610.1988.hed2801060_2.x","volume":"28","author":"F Lance","year":"1988","unstructured":"Lance, F., Parkes, C., & Wilkinson, M. (1988). Does analgesic abuse cause headaches de novo? Headache, 28(1), 61\u201362.","journal-title":"Headache"},{"key":"200_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1526-4610.2003.03041.x","volume":"43","author":"A Bahra","year":"2003","unstructured":"Bahra, A., Walsh, M., Menon, S., & Goadsby, P. J. (2003). Does chronic daily headache arise de novo in association with regular use of analgesics? Headache, 43, 179\u2013190.","journal-title":"Headache"},{"issue":"1","key":"200_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/ene.12794","volume":"23","author":"P Sarchielli","year":"2016","unstructured":"Sarchielli, P., Corbelli, I., Messina, P., Cupini, L. M., Bernardi, G., Bono, G., et al. (2016). Psychopathological comorbidities in medication-overuse headache: A multicentre clinical study. European Journal of Neurology, 23(1), 85\u201391.","journal-title":"European Journal of Neurology"},{"issue":"2","key":"200_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1176\/appi.neuropsych.20070189","volume":"33","author":"M Ljubisavljevic","year":"2021","unstructured":"Ljubisavljevic, M., Ignjatovic, A., Djordjevic, V., Pesic, M. H., & Ljubisavljevic, S. (2021). Depression, anxiety, stress, and health-related quality of life among patients with medication overuse headache in a tertiary headache center: A cross-sectional study. Journal of Neuropsychiatry and Clinical Neurosciences, 33(2), 132\u2013143.","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"200_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pain.2011.08.018","volume":"153","author":"K Hagen","year":"2012","unstructured":"Hagen, K., Linde, M., Steiner, T. J., Stovner, L. J., & Zwart, J. A. (2012). Risk factors for medication-overuse headache: An 11-year follow-up study. The Nord-Trondelag health studies. Pain, 153, 56\u201361.","journal-title":"Pain"},{"issue":"2","key":"200_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.pain.2010.07.032","volume":"151","author":"G Fritsche","year":"2010","unstructured":"Fritsche, G., Frettloh, J., Huppe, M., Dlugaj, M., Matatko, N., Gaul, C., et al. (2010). Prevention of medication overuse in patients with migraine. Pain, 151(2), 404\u2013413.","journal-title":"Pain"},{"issue":"9","key":"200_CR27","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/j.1468-2982.2006.01175.x","volume":"26","author":"P Rossi","year":"2006","unstructured":"Rossi, P., Di Lorenzo, C., Faroni, J., Cesarino, F., & Nappi, G. (2006). Advice alone vs. structured detoxification programmes for medication overuse headache: A prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia, 26(9), 1097\u20131105.","journal-title":"Cephalalgia"},{"key":"200_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/29-2377-14-10","volume":"14","author":"P Rossi","year":"2013","unstructured":"Rossi, P., Faroni, J. V., Tassorelli, C., & Nappi, G. (2013). Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): A prospective, randomized, open-label trial. The Journal of Headache and Pain, 14, 10. https:\/\/doi.org\/10.1186\/29-2377-14-10","journal-title":"The Journal of Headache and Pain"},{"issue":"1","key":"200_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1468-1331.2010.03094.x","volume":"18","author":"RB Grande","year":"2011","unstructured":"Grande, R. B., Aaseth, K., Benth, J. S., Lundqvist, C., & Russell, M. B. (2011). Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. European Journal of Neurology, 18(1), 129\u2013137.","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"200_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ene.12850","volume":"23","author":"ES Kristoffersen","year":"2016","unstructured":"Kristoffersen, E. S., Straand, J., Russell, M. B., & Lundqvist, C. (2016). Disability, anxiety and depression in patients with medication-overuse headache in primary care\u2014The BIMOH study. European Journal of Neurology, 23(Suppl 1), 28\u201335.","journal-title":"European Journal of Neurology"},{"issue":"5","key":"200_CR31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ane.12759","volume":"136","author":"ES Kristoffersen","year":"2017","unstructured":"Kristoffersen, E. S., Straand, J., Benth, J. S., Russell, M. B., & Lundqvist, C. (2017). Predictors of successful primary care detoxification treatment for medication-overuse headache. Acta Neurologica Scandinavica, 136(5), 486\u2013494.","journal-title":"Acta Neurologica Scandinavica"},{"issue":"8","key":"200_CR32","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/ene.13632","volume":"25","author":"I Corbelli","year":"2018","unstructured":"Corbelli, I., Sarchielli, P., Eusebi, P., Cupini, L. M., Caproni, S., & Calabresi, P. (2018). Early management of patients with medication-overuse headache: Results from a multicentre clinical study. European Journal of Neurology, 25(8), 1027\u20131033.","journal-title":"European Journal of Neurology"},{"issue":"3","key":"200_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/head.13020","volume":"57","author":"SJ Krause","year":"2017","unstructured":"Krause, S. J., Stillman, M. J., Tepper, D. E., & Zajac, D. (2017). A prospective cohort study of outpatient interdisciplinary rehabilitation of chronic headache patients. Headache, 57(3), 428\u2013440.","journal-title":"Headache"},{"issue":"5","key":"200_CR34","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1526-4610.2006.00428.x","volume":"46","author":"JF Rothrock","year":"2006","unstructured":"Rothrock, J. F., Parada, V. A., Sims, C., Key, K., Walters, N. S., & Zweifler, R. M. (2006). The impact of intensive patient education on clinical outcome in a clinic-based migraine population. Headache, 46(5), 726\u2013731.","journal-title":"Headache"},{"key":"200_CR35","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/088307380101600613","volume":"16","author":"R Hering-Hanit","year":"2001","unstructured":"Hering-Hanit, R., Cohen, A., & Horev, Z. (2001). Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. Journal of Child Neurology, 16, 448\u2013449.","journal-title":"Journal of Child Neurology"},{"issue":"10","key":"200_CR36","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/j.1526-4610.2010.01755.x","volume":"50","author":"F Radat","year":"2010","unstructured":"Radat, F., & Lanteri-Minet, M. (2010). What is the role of dependence-related behavior in medication-overuse headache? Headache, 50(10), 1597\u20131611.","journal-title":"Headache"},{"issue":"7","key":"200_CR37","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10194-012-0469-y","volume":"13","author":"TM Wallasch","year":"2012","unstructured":"Wallasch, T. M., & Kropp, P. (2012). Multidisciplinary integrated headache care: A prospective 12-month follow-up observational study. The Journal of Headache and Pain, 13(7), 521\u2013529.","journal-title":"The Journal of Headache and Pain"},{"issue":"7","key":"200_CR38","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1177\/0333102417736898","volume":"38","author":"LN Carlsen","year":"2018","unstructured":"Carlsen, L. N., Westergaard, M. L., Bisgaard, M., Schytz, J. B., & Jensen, R. H. (2018). National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia, 38(7), 1316\u20131325.","journal-title":"Cephalalgia"},{"issue":"7","key":"200_CR39","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/ene.13318","volume":"24","author":"ES Kristoffersen","year":"2017","unstructured":"Kristoffersen, E. S., Straand, J., Russell, M. B., & Lundqvist, C. (2017). Lasting improvement of medication-overuse headache after brief intervention\u2014A long-term follow-up in primary care. European Journal of Neurology, 24(7), 883\u2013891.","journal-title":"European Journal of Neurology"},{"issue":"7","key":"200_CR40","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","volume":"27","author":"HC Diener","year":"2007","unstructured":"Diener, H. C., Bussone, G., Van Oene, J. C., Lahaye, M., Schwalen, S., & Goadsby, P. J. (2007). Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia, 27(7), 814\u2013823.","journal-title":"Cephalalgia"},{"issue":"2","key":"200_CR41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","volume":"47","author":"SD Silberstein","year":"2007","unstructured":"Silberstein, S. D., Lipton, R. B., Dodick, D. W., Freitag, F. G., Ramadan, N., Mathew, N., et al. (2007). Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache, 47(2), 170\u2013180.","journal-title":"Headache"},{"issue":"8","key":"200_CR42","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1526-4610.2009.01508.x","volume":"49","author":"S Silberstein","year":"2009","unstructured":"Silberstein, S., Lipton, R., Dodick, D., Freitag, F., Mathew, N., Brandes, J., et al. (2009). Topiramate treatment of chronic migraine: A randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache, 49(8), 1153\u20131162.","journal-title":"Headache"},{"issue":"5","key":"200_CR43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/01.WNF.000022888.49044.99","volume":"29","author":"D Mei","year":"2006","unstructured":"Mei, D., Ferraro, D., Zelano, G., Capuano, A., Vollono, C., Gabriele, C., et al. (2006). Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clinical Neuropharmacology, 29(5), 269\u2013275.","journal-title":"Clinical Neuropharmacology"},{"issue":"7","key":"200_CR44","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora, S. K., Dodick, D. W., Turkel, C. C., DeGryse, R. E., Silberstein, S. D., Lipton, R. B., et al. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia, 30(7), 793\u2013803.","journal-title":"Cephalalgia"},{"issue":"7","key":"200_CR45","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener, H. C., Dodick, D. W., Aurora, S. K., Turkel, C. C., DeGryse, R. E., Lipton, R. B., et al. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia, 30(7), 804\u2013814.","journal-title":"Cephalalgia"},{"issue":"1\u20132","key":"200_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","volume":"331","author":"SD Silberstein","year":"2013","unstructured":"Silberstein, S. D., Blumenfeld, A. M., Cady, R. K., Turner, I. M., Lipton, R. B., Diener, H. C., et al. (2013). OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. Journal of the Neurological Sciences, 331(1\u20132), 48\u201356.","journal-title":"Journal of the Neurological Sciences"},{"issue":"20","key":"200_CR47","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper, S. J., Diener, H. C., Ashina, M., Brandes, J. L., Friedman, D. I., Reuter, U., et al. (2019). Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology, 92(20), e2309\u2013e2320.","journal-title":"Neurology"},{"issue":"3","key":"200_CR48","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/0333102420966658","volume":"41","author":"DW Dodick","year":"2021","unstructured":"Dodick, D. W., Doty, E. G., Aurora, S. K., Ruff, D. D., Stauffer, V. L., Jedynak, J., et al. (2021). Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia, 41(3), 340\u2013352.","journal-title":"Cephalalgia"},{"issue":"10","key":"200_CR49","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners, W. M., Kim, B. K., L\u00e1inez, M. J. A., Lanteri-Minet, M., Pozo-Rosich, P., Wang, S., et al. (2020). Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): A multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurology, 19(10), 814\u2013825.","journal-title":"Lancet Neurology"},{"issue":"1","key":"200_CR50","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","volume":"21","author":"SD Silberstein","year":"2020","unstructured":"Silberstein, S. D., Cohen, J. M., Seminerio, M. J., Yang, R., Ashina, S., & Katsarava, Z. (2020). The impact of fremanezumab on medication overuse in patients with chronic migraine: Subgroup analysis of the HALO CM study. The Journal of Headache and Pain, 21(1), 114.","journal-title":"The Journal of Headache and Pain"},{"key":"200_CR51","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari, M. D., Diener, H. C., Ning, X., Galic, M., Cohen, J. M., Yang, R., et al. (2019). Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial. Lancet, 394, 1030\u20131040.","journal-title":"Lancet"},{"issue":"3","key":"200_CR52","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina, M., Saper, J., Cady, R., Schaeffler, B. A., Biondi, D. M., Hirman, J., et al. (2020). Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia, 40(3), 241\u2013254.","journal-title":"Cephalalgia"},{"issue":"13","key":"200_CR53","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton, R. B., Goadsby, P. J., Smith, J., Schaeffler, B. A., Biondi, D. M., Hirman, J., et al. (2020). Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology, 94(13), e1365\u2013e1377.","journal-title":"Neurology"},{"issue":"1","key":"200_CR54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/head.14036","volume":"61","author":"HC Diener","year":"2021","unstructured":"Diener, H. C., Marmura, M. J., Tepper, S. J., Cowan, R., Starling, A. J., Diamond, M. L., et al. (2021). Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2. Headache, 61(1), 125\u2013136.","journal-title":"Headache"},{"key":"200_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/head.14206):1421-31","author":"MJ Marmura","year":"2021","unstructured":"Marmura, M. J., Diener, H.-C., Cowan, R. P., Tepper, S. J., Diamond, M. L., Starling, A. J., et al. (2021). Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Headache: The Journal of Head and Face Pain. https:\/\/doi.org\/10.1111\/head.14206):1421-31","journal-title":"Headache: The Journal of Head and Face Pain"},{"issue":"12","key":"200_CR56","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/jnnp-2020-324674","volume":"92","author":"JC Ray","year":"2021","unstructured":"Ray, J. C., Kapoor, M., Stark, R. J., Wang, S. J., Bendtsen, L., Matharu, M., et al. (2021). Calcitonin gene related peptide in migraine: Current therapeutics, future implications and potential off-target effects. Journal of Neurology, Neurosurgery and Psychiatry, 92(12), 1325\u20131334.","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"200_CR57","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1100\/tsw.2002.806","volume":"2","author":"L Edvinsson","year":"2002","unstructured":"Edvinsson, L. (2002). Calcitonin gene-related peptide (CGRP) in cerebrovascular disease. The Scientific World Journal, 2, 1484\u20131490.","journal-title":"The Scientific World Journal"},{"issue":"1","key":"200_CR58","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0014-2999(93)90645-X","volume":"250","author":"BM Peskar","year":"1993","unstructured":"Peskar, B. M., Wong, H. C., Walsh, J. H., & Holzer, P. (1993). A monoclonal antibody to calcitonin gene-related peptide abolishes capsaicin-induced gastroprotection. European Journal of Pharmacology, 250(1), 201\u2013203.","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"200_CR59","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/HYPERTENSIONAHA.113.02517","volume":"63","author":"SJ Smillie","year":"2014","unstructured":"Smillie, S. J., King, R., Kodji, X., Outzen, E., Pozsgai, G., Fernandes, E., et al. (2014). An ongoing role of \u03b1-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension, 63(5), 1056\u20131062.","journal-title":"Hypertension"},{"issue":"8","key":"200_CR60","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/head.14198","volume":"61","author":"ID Breen","year":"2021","unstructured":"Breen, I. D., Mangold, A. R., & VanderPluym, J. H. (2021). The evolving understanding of risk with calcitonin gene-related peptide monoclonal antibodies based on real-world data: A focus on hypertension and Raynaud phenomenon. Headache: The Journal of Head and Face Pain, 61(8), 1274\u20131276.","journal-title":"Headache: The Journal of Head and Face Pain"},{"issue":"8","key":"200_CR61","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/head.13596","volume":"59","author":"RW Evans","year":"2019","unstructured":"Evans, R. W. (2019). Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists. Headache, 59(8), 1360\u20131364.","journal-title":"Headache"},{"issue":"8","key":"200_CR62","doi-asserted-by":"publisher","first-page":"e04625","DOI":"10.1002\/ccr3.4625","volume":"9","author":"AH Manickam","year":"2021","unstructured":"Manickam, A. H., Buture, A., Tomkins, E., & Ruttledge, M. (2021). Raynaud\u2019s phenomenon secondary to erenumab in a patient with chronic migraine. Clin Case Rep., 9(8), e04625.","journal-title":"Clin Case Rep."},{"issue":"5","key":"200_CR63","doi-asserted-by":"publisher","first-page":"B354","DOI":"10.1093\/gerona\/51A.5.B354","volume":"51","author":"Z Khalil","year":"1996","unstructured":"Khalil, Z., & Helme, R. (1996). Sensory peptides as neuromodulators of wound healing in aged rats. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 51(5), B354\u2013B361.","journal-title":"Journals of Gerontology. Series A, Biological Sciences and Medical Sciences"},{"key":"200_CR64","doi-asserted-by":"crossref","unstructured":"Yin, Q., Sun, L., Cai, X., Lou, F., Sun, Y., Wang, B., et al. (2022). Lidocaine ameliorates psoriasis by obstructing pathogenic CGRP signaling-mediated sensory neuron-dendritic cell communication. Journal of Investigative Dermatology.","DOI":"10.1016\/j.jid.2022.01.002"},{"issue":"8","key":"200_CR65","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.euroneuro.2014.03.010","volume":"24","author":"P Sarchielli","year":"2014","unstructured":"Sarchielli, P., Messina, P., Cupini, L. M., Tedeschi, G., Di Piero, V., Livrea, P., et al. (2014). Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial. European Neuropsychopharmacology, 24(8), 1289\u20131297.","journal-title":"European Neuropsychopharmacology"},{"issue":"8","key":"200_CR66","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10194-012-0490-1","volume":"13","author":"LA Pini","year":"2012","unstructured":"Pini, L. A., Guerzoni, S., Cainazzo, M. M., Ferrari, A., Sarchielli, P., Tiraferri, I., et al. (2012). Nabilone for the treatment of medication overuse headache: Results of a preliminary double-blind, active-controlled, randomized trial. The Journal of Headache and Pain, 13(8), 677\u2013684.","journal-title":"The Journal of Headache and Pain"},{"issue":"2","key":"200_CR67","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/WNF.0b013e318210ecc9","volume":"34","author":"B Rizzato","year":"2011","unstructured":"Rizzato, B., Leone, G., Misaggi, G., Zivi, I., & Diomedi, M. (2011). Efficacy and tolerability of pregabalin versus topiramate in the prophylaxis of chronic daily headache with analgesic overuse: An open-label prospective study. Clinical Neuropharmacology, 34(2), 74\u201378.","journal-title":"Clinical Neuropharmacology"},{"issue":"2","key":"200_CR68","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jams.2020.01.001","volume":"13","author":"RT Rudra","year":"2020","unstructured":"Rudra, R. T., Gordin, V., & Xu, L. (2020). Acupuncture in the management of medication overuse and drug-induced aseptic meningitis headache: A case report. Journal of Acupuncture and Meridian Studies, 13(2), 58\u201360.","journal-title":"Journal of Acupuncture and Meridian Studies"},{"issue":"4","key":"200_CR69","first-page":"401","volume":"9","author":"A Roceanu","year":"2014","unstructured":"Roceanu, A., Antochi, F., & Bajenaru, O. (2014). Chronic migraine\u2014New treatment options. Maedica (Bucur)., 9(4), 401\u2013404.","journal-title":"Maedica (Bucur)."},{"issue":"5","key":"200_CR70","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00482-017-0214-1","volume":"31","author":"P Kropp","year":"2017","unstructured":"Kropp, P., Meyer, B., Dresler, T., Fritsche, G., Gaul, C., Niederberger, U., et al. (2017). Entspannungsverfahren und verhaltenstherapeutische Interventionen zur Behandlung der Migr\u00e4ne. Leitlinie der Deutschen Migr\u00e4ne- und Kopfschmerzgesellschaft. Schmerz, 31(5), 433\u2013447.","journal-title":"Schmerz"},{"issue":"1","key":"200_CR71","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s10194-016-0679-9","volume":"17","author":"M Rausa","year":"2016","unstructured":"Rausa, M., Palomba, D., Cevoli, S., Lazzerini, L., Sancisi, E., Cortelli, P., et al. (2016). Biofeedback in the prophylactic treatment of medication overuse headache: A pilot randomized controlled trial. The Journal of Headache and Pain, 17(1), 87.","journal-title":"The Journal of Headache and Pain"},{"issue":"1","key":"200_CR72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s10194-017-0728-z","volume":"18","author":"L Grazzi","year":"2017","unstructured":"Grazzi, L., Sansone, E., Raggi, A., D\u2019Amico, D., De Giorgio, A., Leonardi, M., et al. (2017). Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with chronic migraine: An effectiveness trial with a one-year follow-up. The Journal of Headache and Pain, 18(1), 15.","journal-title":"The Journal of Headache and Pain"},{"issue":"14","key":"200_CR73","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1177\/0333102416631960","volume":"36","author":"S Bottiroli","year":"2016","unstructured":"Bottiroli, S., Viana, M., Sances, G., Ghiotto, N., Guaschino, E., Galli, F., et al. (2016). Psychological factors associated with failure of detoxification treatment in chronic headache associated with medication overuse. Cephalalgia, 36(14), 1356\u20131365.","journal-title":"Cephalalgia"},{"issue":"1","key":"200_CR74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/0333102415578430","volume":"36","author":"ML Westergaard","year":"2016","unstructured":"Westergaard, M. L., Glumer, C., Hansen, E. H., & Jensen, R. H. (2016). Medication overuse, healthy lifestyle behaviour and stress in chronic headache: Results from a population-based representative survey. Cephalalgia, 36(1), 15\u201328.","journal-title":"Cephalalgia"},{"issue":"10","key":"200_CR75","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/j.1468-2982.2006.01190.x","volume":"26","author":"P Zeeberg","year":"2006","unstructured":"Zeeberg, P., Olesen, J., & Jensen, R. (2006). Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness. Cephalalgia, 26(10), 1192\u20131198.","journal-title":"Cephalalgia"},{"issue":"5","key":"200_CR76","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/jnnp-2014-308548","volume":"86","author":"ES Kristoffersen","year":"2015","unstructured":"Kristoffersen, E. S., Straand, J., Vetvik, K. G., Benth, J. S., Russell, M. B., & Lundqvist, C. (2015). Brief intervention for medication-overuse headache in primary care. The BIMOH study: A double-blind pragmatic cluster randomised parallel controlled trial. Journal of Neurology, Neurosurgery & Psychiatry, 86(5), 505\u2013512.","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"11","key":"200_CR77","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1177\/0333102411412088","volume":"31","author":"C Creac'h","year":"2011","unstructured":"Creac\u2019h, C., Frappe, P., Cancade, M., Laurent, B., Peyron, R., Demarquay, G., et al. (2011). In-patient versus out-patient withdrawal programmes for medication overuse headache: A 2-year randomized trial. Cephalalgia, 31(11), 1189\u20131198.","journal-title":"Cephalalgia"},{"issue":"9","key":"200_CR78","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/0333102414521508","volume":"34","author":"C Tassorelli","year":"2014","unstructured":"Tassorelli, C., Jensen, R., Allena, M., De Icco, R., Sances, G., Katsarava, Z., et al. (2014). A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia, 34(9), 645\u2013655.","journal-title":"Cephalalgia"},{"issue":"4","key":"200_CR79","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0333102415593088","volume":"36","author":"CC Chiang","year":"2016","unstructured":"Chiang, C. C., Schwedt, T. J., Wang, S. J., & Dodick, D. W. (2016). Treatment of medication-overuse headache: A systematic review. Cephalalgia, 36(4), 371\u2013386.","journal-title":"Cephalalgia"},{"issue":"2","key":"200_CR80","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1468-2982.2008.01711.x","volume":"29","author":"K Hagen","year":"2009","unstructured":"Hagen, K., Albretsen, C., Vilming, S. T., Salvesen, R., Gronning, M., Helde, G., et al. (2009). Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia, 29(2), 221\u2013232.","journal-title":"Cephalalgia"},{"issue":"11","key":"200_CR81","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1177\/0333102412451363","volume":"32","author":"SB Munksgaard","year":"2012","unstructured":"Munksgaard, S. B., Bendtsen, L., & Jensen, R. H. (2012). Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: A comparison of two consecutive treatment methods in an open-label design. Cephalalgia, 32(11), 834\u2013844.","journal-title":"Cephalalgia"},{"issue":"9","key":"200_CR82","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaneurol.2020.1179","volume":"77","author":"LN Carlsen","year":"2020","unstructured":"Carlsen, L. N., Munksgaard, S. B., Nielsen, M., Engelstoft, I. M. S., Westergaard, M. L., Bendtsen, L., et al. (2020). Comparison of 3 treatment strategies for medication overuse headache: A randomized clinical trial. JAMA Neurology, 77(9), 1069\u20131078.","journal-title":"JAMA Neurology"},{"issue":"6","key":"200_CR83","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/ejp.1383","volume":"23","author":"IMS Engelstoft","year":"2019","unstructured":"Engelstoft, I. M. S., Carlsen, L. N., Munksgaard, S. B., Nielsen, M., Jensen, R. H., & Bendtsen, L. (2019). Complete withdrawal is the most feasible treatment for medication-overuse headache: A randomized controlled open-label trial. European Journal of Pain, 23(6), 1162\u20131170.","journal-title":"European Journal of Pain"},{"issue":"4","key":"200_CR84","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1526-4610.2004.04093.x","volume":"44","author":"FG Freitag","year":"2004","unstructured":"Freitag, F. G., Lake, A., 3rd., Lipton, R., Cady, R., Diamond, S., Silberstein, S., et al. (2004). Inpatient treatment of headache: An evidence-based assessment. Headache, 44(4), 342\u2013360.","journal-title":"Headache"},{"issue":"7","key":"200_CR85","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/ene.14268","volume":"27","author":"HC Diener","year":"2020","unstructured":"Diener, H. C., Antonaci, F., Braschinsky, M., Evers, S., Jensen, R., Lainez, M., et al. (2020). European Academy of Neurology guideline on the management of medication-overuse headache. European Journal of Neurology, 27(7), 1102\u20131116.","journal-title":"European Journal of Neurology"},{"key":"200_CR86","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1212\/WNL.57.9.1694","volume":"57","author":"Z Katsarava","year":"2001","unstructured":"Katsarava, Z., Fritsche, G., Muessig, M., Diener, H. C., & Limmroth, V. (2001). Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology, 57, 1694\u20131698.","journal-title":"Neurology"},{"issue":"1","key":"200_CR87","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1212\/01.wnl.0000263652.46222.e8","volume":"69","author":"MG Boe","year":"2007","unstructured":"Boe, M. G., Mygland, A., & Salvesen, R. (2007). Prednisolone does not reduce withdrawal headache: A randomized, double-blind study. Neurology, 69(1), 26\u201331.","journal-title":"Neurology"},{"issue":"3","key":"200_CR88","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0333102412462638","volume":"33","author":"K Rabe","year":"2013","unstructured":"Rabe, K., Pageler, L., Gaul, C., Lampl, C., Kraya, T., Foerderreuther, S., et al. (2013). Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind, placebo-controlled study. Cephalalgia, 33(3), 202\u2013207.","journal-title":"Cephalalgia"},{"issue":"1","key":"200_CR89","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-017-0763-9","volume":"18","author":"S Cevoli","year":"2017","unstructured":"Cevoli, S., Giannini, G., Favoni, V., Terlizzi, R., Sancisi, E., Nicodemo, M., et al. (2017). Treatment of withdrawal headache in patients with medication overuse headache: A pilot study. The Journal of Headache and Pain, 18(1), 56.","journal-title":"The Journal of Headache and Pain"},{"issue":"1","key":"200_CR90","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/head.12487","volume":"55","author":"F Taghdiri","year":"2015","unstructured":"Taghdiri, F., Togha, M., Razeghi Jahromi, S., & Paknejad, S. M. (2015). Celecoxib vs prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind clinical trial. Headache, 55(1), 128\u2013135.","journal-title":"Headache"},{"key":"200_CR91","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1468-2982.2000.00028.x","volume":"20","author":"AV Krymchantowski","year":"2000","unstructured":"Krymchantowski, A. V., & Barbosa, J. S. (2000). Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia, 20, 107\u2013113.","journal-title":"Cephalalgia"},{"issue":"11","key":"200_CR92","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s10072-017-3098-z","volume":"38","author":"M Paolucci","year":"2017","unstructured":"Paolucci, M., Altamura, C., Brunelli, N., Rizzo, A. C., Assenza, F., Pasqualetti, P., et al. (2017). Methylprednisolone plus diazepam i.v. as bridge therapy for medication overuse headache. Neurological Sciences, 38(11), 2025\u20132029.","journal-title":"Neurological Sciences"},{"issue":"1","key":"200_CR93","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/head.12979","volume":"57","author":"A Raggi","year":"2017","unstructured":"Raggi, A., Giovannetti, A. M., Leonardi, M., Sansone, E., Schiavolin, S., Curone, M., et al. (2017). Predictors of 12-months relapse after withdrawal treatment in hospitalized patients with chronic migraine associated with medication overuse: A longitudinal observational study. Headache, 57(1), 60\u201370.","journal-title":"Headache"},{"issue":"1","key":"200_CR94","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0333102418783317","volume":"39","author":"S Bottiroli","year":"2019","unstructured":"Bottiroli, S., Allena, M., Sances, G., De Icco, R., Avenali, M., Fadic, R., et al. (2019). Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A six-month follow-up of the COMOESTAS Project. Cephalalgia, 39(1), 135\u2013147.","journal-title":"Cephalalgia"},{"issue":"4\u20136","key":"200_CR95","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000504620","volume":"82","author":"H Liu","year":"2019","unstructured":"Liu, H., Zhang, M., Chen, X., Sun, S., Dong, Z., & Yu, S. (2019). Rates and predictors of relapse in medication overuse headache: A clinic-based study from China. European Neurology, 82(4\u20136), 68\u201374.","journal-title":"European Neurology"},{"issue":"2","key":"200_CR96","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0333102417737779","volume":"38","author":"LN Carlsen","year":"2018","unstructured":"Carlsen, L. N., Munksgaard, S. B., Jensen, R. H., & Bendtsen, L. (2018). Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial. Cephalalgia, 38(2), 225\u2013236.","journal-title":"Cephalalgia"},{"issue":"2","key":"200_CR97","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/0333102416683918","volume":"38","author":"JJ Zidverc-Trajkovic","year":"2018","unstructured":"Zidverc-Trajkovic, J. J., Pekmezovic, T., Jovanovic, Z., Pavlovic, A., Mijajlovic, M., Radojicic, A., et al. (2018). Long-term predictors of remission in patients treated for medication-overuse headache at a specialized headache center: A prospective cohort study. Cephalalgia, 38(2), 265\u2013273.","journal-title":"Cephalalgia"},{"key":"200_CR98","first-page":"348","volume":"12","author":"C Gaul","year":"2011","unstructured":"Gaul, C., van Doorn, C., Webering, N., Dlugaj, M., Katsarava, Z., Diener, H., et al. (2011). Efficacy of a headache specific multidisciplinary treatment program and adherence to treatment in a tertiary headache center. The Journal of Headache and Pain, 12, 348.","journal-title":"The Journal of Headache and Pain"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-022-00200-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-022-00200-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-022-00200-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T22:02:37Z","timestamp":1661724157000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-022-00200-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1186\/s42466-022-00200-0","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Does not apply.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors and the German Society of Neurology approved the submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"All participants in the guideline have submitted their declarations of interest (AWMF form for the declaration of interests in the context of guideline projects) to the coordinator or the Editorial Office for Guidelines of the DGN in time and completely filled out. The evaluation of the declarations of interest with regard to thematic relevance to the guideline was carried out by anonymous reviewers. Details of the COls statement can be found in the German version of the guideline. For reasons of transparency, the interests of the participants and the consequences drawn from them are listed on the respective AWMF guideline website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}